A metastatic cancer develops by accumulation of mutations in genes that control growth, survival and spreading. The latter genes have not yet been identi®ed. In lymph node metastases of head and neck squamous cell carcinomas (HNSCC), we found mutations in the MET oncogene, which encodes the tyrosine kinase receptor for Scatter Factor, a cytokine that stimulates epithelial cell motility and invasiveness during embryogenesis and tissue remodeling. We identi®ed two somatic mutations: the Y1230C, known as a MET germline mutation which predisposes to hereditary renal cell carcinoma, and the Y1235D that is novel and changes a critical tyrosine, known to regulate MET kinase activity. The mutated MET receptors are constitutively active and confer an invasive phenotype to transfected cells. Interestingly, cells carrying the MET mutations are selected during metastatic spread: transcripts of the mutant alleles are highly represented in metastases, but barely detectable in primary tumors. These data indicate that cells expressing mutant MET undergo clonal expansion during HNSCC progression and suggest that MET might be one of the long sought oncogenes controlling progression of primary cancers to metastasis. Oncogene (2000) 19, 1547 ± 1555.
Introduction
Cancer metastasis is a multi-step process, involving local invasion, intravasation in lymph and blood vessels, extravasation and growth at secondary sites (Fidler and Ellis, 1994) . It is the result of a highly selective competition favoring cell subpopulations of the primary tumor which have an invasive-metastatic phenotype. Genetic alterations capable of inducing this phenotype have long been sought and it is unclear whether tumorigenicity and metastasis are under separate genetic control. Loss of onco-suppressor genes and activation of oncogenes have been associated to stages of cancer progression, but none of these alterations has been conclusively linked to metastasis.
The MET proto-oncogene encodes the tyrosine kinase receptor (Giordano et al., 1989) for Scatter Factor (also known as Hepatocyte Growth Factor, SF/ IIGF; Bottaro et al., 1991; Naldini et al., 1991) , a multifunctional cytokine stimulating cell proliferation, dissociation, motility and extracellular matrix invasion in vitro and during embryonal development (Bladt et al., 1995; Maina et al., 1996) . A role for MET in human tumor formation has been documented. The oncogene is overexpressed in tumors of speci®c histotypes, including thyroid (Di Renzo et al., 1992) and pancreatic carcinomas (Di Renzo et al., 1995b) , and is ampli®ed in liver metastases of colorectal carcinomas (Di Renzo et al., 1995a) . Germline missense mutations in the tyrosine kinase domain were detected in the majority of hereditary papillary renal cell carcinomas (HPRCC) Olivero et al., 1999) , while somatic mutations have been found in a small proportion of sporadic papillary kidney carcinomas and in childhood hepatocellular carcinomas (Park et al., 1999) . In patients with invasive breast carcinoma, tumor expression of either MET (Ghoussoub et al., 1998) or its ligand SF/HGF (Yamashita et al., 1994) was an independent predictor of decreased survival, suggesting a role for the MET receptor in tumor aggressive behavior and progression. The concept that MET drives cells to invade and to metastasize has been validated in the mouse, using either transfected cells (Rong et al., 1994; Giordano et al., 1997; Meiners et al., 1998) or transgenic animals (Liang et al., 1996; Jeers et al., 1998; Otsuka et al., 1998) . Here we show that human carcinoma cells harboring a mutation in the MET gene undergo clonal expansion during metastatic spreading to lymph nodes.
Results

Identification of MET gene mutations in HNSCC metastases
We selected the lymph node metastasis of head and neck squamous cell carcinoma (HNSCC) as a model. These tumor cells spread to regional lymph nodes, usually colonizing the nearest nodes of the chain ®rst, and later disseminating to the more distant ones (anatomically classi®ed in`levels', see Figure 1A ). In a previous study, we analysed a large number of HNSCCs and their metastases, and found that the MET receptor is overexpressed in most samples (Galeazzi et al., 1997) . This has been also reported for oral and laryngeal squamous cell carcinomas using immunohistochemical detection (Marshall and Kornberg, 1998; Sawatsubashi et al., 1998) . For this study, 15 primary tumors were harvested, together with a total of 117 either metastatic or clinically unaected lymph nodes from the same patients (Table 1) . We took advantage of the fact that the MET protooncogene is not expressed in normal lymph nodes (Iyer et al., 1990; Di Renzo et al., 1991) and, thus that MET mRNAs detected in nodes must be from metastatic tumor cells. As expected, using RT ± PCR, expression of the MET gene was detected in all primary HNSCCs and in their metastases (Table 1) . Expression of the MET receptor in the same tumors was demonstrated by Western blot analysis (not shown). Immunohistochemistry con®rmed MET receptor localization in tumor cells; Figure 1B shows a micro-metastasis which appeared as a small tumor mass within the lymphatic tissues and could be stained with anti-MET antibodies. By RT ± PCR MET-speci®c sequences were ampli®ed from 46/117 lymph nodes resected from these 15 HNSCCs: RT ± PCR analysis not only paralleled histo-pathological analysis, but also allowed identi®ca-tion of additional occult metastases (Table 1) . Table 2 shows the detailed comparison of results obtained with pathology and RT ± PCR detection of MET sequences in four cases.
In MET-speci®c RT ± PCR products, we sequenced the kinase domain, where germline and somatic mutations found in papillary renal carcinomas have been previously located (Schmidt et al., , 1998 Fischer et al., 1998; Olivero et al., 1999) . We identi®ed MET gene somatic mutations in ten lymph node metastases (out of the 46 MET-positive metastases) harvested from 4/15 HNSCC cases studied. By direct sequencing we found the Y1230C MET mutation in metastases of one patient (case 88, Table 2 ). This mutation was previously identi®ed in hereditary and sporadic renal cell carcinomas . In lymph node metastases from other three cases (65, 66 and 79, Table 2 ) we found the same novel point mutation: this was a T
3703
?G mutation at codon 1235 in exon 19, which results in the substitution of tyrosine with aspartic acid. The pilot study of 46 metastatic lymph nodes using automated sequencing was con®rmed by manual sequencing (Figure 2 ). We did not ®nd the Y1230C or the Y1235D mutations in the germline of the patients or in their normal adjacent matched tissue. Interestingly, by direct sequencing of RT ± PCR products, we did not detect these two mutations either in any of the four primary tumors or (in two cases) in the metastases nearest to the primary tumors (Figure 2 ).
Both the Y1230C and the Y1235D mutations in transcripts from HNSCC metastases were also detected using mutant-allele-speci®c ampli®cation in end-point RT ± PCR (MASA, Hasegawa et al., 1995) . The latter method was used to analyse the whole series of samples. Moreover, MASA of the case 65 with the MET Y1235D primer demonstrated that not only distant metastases, but also primary tumors and the nearest metastases were positive (data not shown).
Percentage of mutant MET allele RNA in HNSCC
We established the relative expression of wild-type and mutant MET alleles in primary tumors and metastases harvested from the four positive cases, by means of realtime quantitative RT ± PCR with wild-type/mutantspeci®c primers. Working conditions of real-time PCR Levels are classi®ed in Figure 1a . c Routine pathology and MET-speci®c RT ± PCR were performed on the two halves of selected nodes of the lymphatic chain, as described in the Materials and methods section. Other 354 nodes were resected at surgery and examined only by routine pathology for staging. From primary tumors, normal mucosa and lymph nodes, RT ± PCR products corresponding to exons 16 ± 19 were directly sequenced; cDNAs were also examined by MASA in end-point PCR. wt: normal MET sequence in exons 16 ± 19. The T3703G mutation results in the Y1235D substitution; the A3689G mutation resulting in the Y1230C substitution Figure 1a ; c RT ± PCR products corresponding to exons 16 ± 19 were directly sequenced; cDNAs were also examined by MASA in end-point PCR; when feasible, quantitative MASA in real-time PCR was used to measure the relative amount of mutated sequence, indicated in brackets; when MET mutated sequences represented less than 10% of the total, they were detectable only by MASA. wt: normal MET sequence in exons 16 ± 19; nd: not done, as RT ± PCR was negative (neg); not meas.: amount not measured, due to limited availability of the samples (case no. 79) or unfeasibility of the quantitative MASA assay in real-time PCR with the A3689G-speci®c primer (case no. 88) with TaqMan assay allowed the use of the MET Y1235D -speci®c primer, but not of the MET Y1230C -speci®c primer. As shown in Figure 3 , we compared the threshold cycles (C T ) of ampli®cations, obtained with wild-type and mutant allele-speci®c primers on the same cDNA sample. The knowledge of C T values allows us to calculate the relative percentage of wildtype and mutated MET sequences in samples, reported in Table 2 . Transcripts of the mutant MET Y1235D allele represent 50% of MET sequences in metastases, but only 2 ± 6% of those present in primary tumors. These data suggest that a very small number of cells expressing the MET Y1235D gene were already present in Figure 2 Detection of the T3703G mutation (resulting in the Y1235D substitution) in MET-speci®c transcripts. Direct sequencing of RT ± PCR products from samples of cases 65 and 79. In both cases mutated sequences were detected in nodal metastases at levels III-V, but neither in the primary tumor (ca) nor in the nodal metastases (ln) at level II. Sample legend is in Table 2 Figure 3 the primary tumor mass and that a progressive increase of these cells occurred during the metastatic spread. As real-time RT ± PCR with MET Y1235D primer allowed us to count low percentage of mutated sequences, we re-screened all the other 11 cases that were negative after RT ± PCR followed by direct sequencing. We did not ®nd the same mutation in the samples derived from these 11 cases (data not shown). These data imply that this genetic lesion does not occur frequently and also suggest that its occurrence confers a selective advantage to neoplastic cells.
Detection of mutant MET allele in genomic DNA in HNSCC
To prove unequivocally the presence of the mutated MET alleles in HNSCC, we examined sample genomic DNAs by means of SSCP analysis. As mentioned before, the germline of patients was negative. SSCP analysis revealed the presence of mutant alleles in primary tumors and nodal metastases. Figure 4A shows a representative experiment, where sequencing of the ampli®ed conformers con®rmed the presence of the MET Y1235D allele in tumors and metastases ( Figure 4B ). Mutant alleles were also detected and quanti®ed using real-time quantitative PCR. The percentage of wild-type and mutant alleles was calculated in primary tumors and metastases more than 3 cm in greatest dimension. In these specimens, genomic DNA should derive almost entirely from tumor tissue. As shown in Figure 3E ,F the percentage of mutated sequences is higher in metastatic lymph nodes, suggesting again that the number of cells carrying MET mutated sequences increases in metastases.
Biological activity of the Y1235D mutation
It has been shown that all the MET mutations identi®ed in papillary renal cell carcinomas, including the Y1230C that we found in HNSCC metastases, activate the kinase activity of the MET receptor and are oncogenic (Bardelli et al., 1998; Jeers et al., 1997; Olivero et al., 1999) . In particular, the MET Y1230C mutant receptor was shown to be very eective in inducing anchorage-independent growth and an invasive phenotype in transfected cells (Giordano et al., 2000) .
As the Y1235D mutation is novel, we introduced it in the human MET cDNA and examined its activity in biochemical and biological assays. The Y?D change caused activation of the kinase in the absence of the ligand, as shown by the enhanced phoshorylation of an exogenous substrate ( Figure 5A ).
Biological assays were carried out in epithelial cells, as these cells physiologically express MET receptor. Moreover, germline mutations in the MET kinase domain result in the development of epithelium-derived tumors . It has been previously shown that expression of the other MET mutants in epithelial cells results in`gain' of biological functions, such as the ability to induce anchorage-independent growth and invasiveness (Michieli et al., 1999) . As most of the epithelial cells express endogenous MET receptors, we stably transfected MPL29 murine epithelial cells (Medico et al., 1996) with chimeric receptors, made of the extracellular domain of the Nerve Growth Factor (NGF) receptor, encoded by the TRK gene, and the trans-membrane and intracellular domains of the MET receptor. The MPL29 cells neither express the TRK gene nor produce NGF (Medico et al., 1996) . As shown in Figure 5B ,C, cells expressing the TRK/MET Y1235D mutant grew in anchorage-independent manner and were able to invade in vitro reconstituted basal membranes. These properties were detected in the absence of added ligand but were further enhanced when the MET kinase of the chimera was activated by ligand-induced dimerization ( Figure  5C ).
Discussion
Our results show that neoplastic cells harboring MET gene activating mutations undergo clonal expansion during the metastatic spreading of head and neck squamous cell carcinomas. We cannot rule out the alternative hypotheses that MET point mutations either occurred randomly or were co-selected with other still unknown genetic lesions, critical for the acquisition of a metastatic phenotype. However, both these hypotheses are unlikely because (l) we (unpublished results) and others have sequenced the MET gene kinase domain from hundreds of human tumors without detecting other mutations than those described here in HNSCC and in papillary renal cell carcinomas; (2) in this study the MET gene was found mutated in dierent amino acid residues in a consistent number of HNSCC metastases; 3) the same mutation was found in multiple metastases from each single patient; (4) the mutations here described are functionally relevant: they are located in the MET gene kinase domain and activate the MET receptor.
The mechanism of MET gene activation by mutations is still unknown. Molecular modeling indicates that some mutations, including the Y1230C and Y1235D, can alter residues located in the activation loop Schmidt et al., 1999) . It is notable that Y1235 is one of the two tyrosines (Y 1234 Y 1235 ) previously identi®ed as the MET receptor major autophosphorylation sites. Their phosphorylation positively regulates receptor kinase activity (Longati et al., 1994) . The Y?D mutation results in a change in amino acid class. The negative charge of the Cells were tested for their ability to form colonies in soft agar, either in the absence (gray bars) or in the presence (black bars) of 100 ng/ml Nerve Growth Factor (NGF). Colonies were counted 3 weeks after seeding, (C) Invasive potential elicited by the MET Y1235D kinase. Invasion was evaluated on stably transfected MPL29 cells. The ability of cells to invade the reconstituted basement membrane made of Matrigel1 in Transwell chambers was measured in the presence or in the absence of NGF. Cells passed through the ®lters and attached to the lower side after 24 h, were ®xed with glutaraldehyde, stained with crystal violet and photographed. The experiment shows that the Y1235D mutation activated the ability of the MET kinase to induce cells to invade aspartic acid probably mimics that of a phosphorylated tyrosine. This mechanism has been proposed to explain constitutive activation of another oncogene, B-Raf, having aspartic acids at corresponding positions (Marais et al., 1997) . Similarly, in other serinethreonine kinases such as Akt/PKB (Sable et al., 1997) and aurora (Bischo et al., 1998) , substitution with aspartic acid of critical threonines, in which phosphorylation activates the enzyme, resulted in constitutive and sustained activity.
The Y1230C and Y1235D mutations appear to be heterozygous in RT ± PCR products, indicating coexpression of wild-type and mutant alleles in the metastases. This is consistent with MET behaving as a dominant oncogene. We show also that the MET kinase harboring the latter mutation is activated and causes anchorage-independent growth when transfected into liver epithelial cells already expressing endogenous receptor.
The Y1230C mutation was shown to be oncogenic Michieli et al., 1999) , but in particular to be very eective in inducing anchorageindependent growth and invasive phenotype in transfected cells (Giordano et al., 2000) . Here we show that the MET Y1235D mutant stimulates epithelial cells to invade reconstituted basement membrane. Its eect was detected in the absence of added ligand and it was enhanced when the MET kinase was stimulated by ligand-mediated dimerization. This is consistent with data showing that all the other MET mutants preserve their responsiveness to the ligand Michieli et al., 1999) . Since the MET receptor ligand is present in plasma and tissues (Masumoto and Yamamoto, 1991; Sonnenberg et al., 1993; Tsubouchi et al., 1991) , ligand availability is probably not a limiting step to activation.
A direct role for the MET receptor signaling in the metastatic behavior of human malignancy has been repeatedly proposed, based on experimental evidence. MET kinase, when experimentally activated by an autocrine circuit (Meiners et al., 1998; Rong et al., 1994) or by the rearrangement with TPR sequences converts immortalized cells into highly tumorigenic and metastatic cells. Moreover, mice expressing the mutationally activated met kinase under the control of methallothionin promoter develop mammary tumors that progress to metastasis . Altogether, these reports suggested that the MET gene might be one of the long sought metastasiseector genes. Here we show that neoplastic cells carrying MET gene activating mutations are selected during the progression of human squamous cell carcinomas. A variety of genetic changes found in primary HNSCC have been associated to genetic progression of this cancer (Califano et al., 1996) . The data presented in this paper indicate that a MET activating mutation might confer the ability to establish metastatic colonies to a subpopulation of HNSCC cells.
Material and methods
Tissues and RNA and DNA extraction
Tumors and lymph nodes were obtained from curative resections of HNSCCs. Patients had not received radio-or chemo-therapy before surgery. Fifteen cases were selected, from which samples of primary tumors and normal mucosa together with a total of 117 lymph nodes were harvested for this study. Other 354 nodes from the same patients were only paran embedded for routine histopathological staging. Each of these nodes (one from each level of the lymphatic chain) was divided in two: one half was frozen in the presence of a cryopreservant or formalin-®xed and paran embedded for routine histopathological examination and immunohistochemistry. The other half was snap-frozen in liquid nitrogen and stored at 7808C until the time of protein, RNA and DNA isolation. Western blot analysis, histopathology and immunohistochemistry were performed as described (Galeazzi et al., 1997) .
Total cellular RNA and DNA were isolated using the TriRiagent TM (Sigma Chem.). Total RNA (1 mg) was used as a template for synthesis of oligodT-primed double stranded cDNA, using M-MLV-RT from BRL (UK). The suitability of the RT reaction product for PCR ampli®cation was ®rst checked by performing a PCR reaction for GAPDH cDNA. MET gene sequences corresponding to exons 16 ± 19 were ampli®ed (nucleotides 3341 ± 3899).
Sequence analysis
RT ± PCR products were directly sequenced after being puri®ed from agarose gels using a Qiagen (Germany) PCR product puri®cation kit. Automatic sequences (forward and reverse) were performed using the ABI Prism 310 (Perkin Elmer) following the manufacturer's protocols. Manual sequencing was carried out by cycle-sequencing using Amersham (UK) Thermo Sequenase with 33 P-labeled dideoxynucleotides. Human MET residues are numbered according to GenBank accession number X54559.
Mutant allele-specific amplification (MASA)
End-point PCR reaction was carried out utilizing a 22 bp long oligonucleotide with the MET gene mutation at the 3'-end as speci®c primer and the corresponding primer without mutation as control. The mutated nucleotide at the 3'-end ampli®es the mutated but not the wild-type sequences, because the single base mismatch at the 3'-end abolishes annealing of the primer (Hasegawa et al., 1995) . End-point MASA was performed in either 30 or 60 cycles for 1 min at 948C, 30 s at 608C, 30 s at 728C.
Real-time PCR with TaqMan detection
To calculate the ratio between mutated and wild-type MET sequences in RNA and DNA from primary tumors and lymph node metastases, allele-speci®c primers were used in real-time PCR with TaqMan detection (ABI Prism 7700 Sequence Detection System, Perkin Elmer Applied Biosystems, Foster City, CA, USA). The TaqMan assay is based on the 5' nuclease activity of Taq polymerase for fragmentation of a dual labeled¯uorogenic hybridization probe. A short sequence speci®c probe is designed and labeled at the two ends with dierent¯uorochromes. As long as the probe is intact, emission of a reported dye at its 5' end is quenched by a second¯uorescence dye at the 3' end. During extension of PCR, Taq polymerase hydrolyses the probe and releases the reporter dye. Release of the dye can be monitored online as an increase of¯uorescence intensity in each test tube. The signal is normalized to an internal reference (DRn) and the software sets the threshold cycle C T when DRn becomes equal to ten standard deviations of the baseline. The number of cycles needed to reach a threshold amount of PCR products depends on the inital concentration of target nucleic acid. We compared threshold cycles of the ampli®cations obtained with the wild-type and mutant allele speci®c probes, using either RT ± PCR product or DNA derived from the same sample. As comparable ampli®cation eciency was obtained using primers and probes designed following manufacturer's protocols, to work under identical cycling conditions, the relative amount of mutated and wild-type sequences is given by the following equation: 2 CT,wt7CT.1235 . We used the Perkin Elmer ABI's Prism 7700 sequence Detection System to monitor emission intensities. RNA used for retro-transcription was ®rst digested with DNase (DNase I, RNase-free, Boehringer Mannheim) and the digestion was checked by PCR using intron primers that amplify MET exon 16 (Olivero et al., 1999) . For TaqMan assay we used the Perkin Elmer TaqMan kit and forward and reverse primers that amplify a 94-bp segment of the target MET cDNA. As forward primers 30 bp long oligonucleotides with and without mutation at the 3'-end were used. The internal complementary probe was: 5'-(6-carboxy-¯uorescein) TGTA-CACAACAA AACAGGTGCAAAGCTGC-3'. For GAPDH measurement we used the Perkin Elmer GAPDH kit.
Single strand conformation polymorphism (SSCP)
SSCP analysis was carried out on exons 16 ± 19. In HNSCC samples carrying MET gene mutations, we detected SSCP changes when we ampli®ed fragments shorter than 190 bp, including codons 1230 and 1235, using the following primer pairs. To obtain a 131 bp fragment: two exonic primers, sense 5'-AGGTTGCTGATTTTGGTCTTG-3' and antisense 5'-CTTTTGAGTTTGCAGACTTTCC-3'. To obtain a 120 bp fragment: two exonic primers, sense 5' -GCTACTT-GAA GACCAAAGCC -3' and antisense 5'-CAGACTTTC-CAAAGCCATCC-3'. To obtain a 190 bp fragment: one sense primer in the intronic¯anking region (5'-AGGTTGCT-GATTTTG GTCTTG-3') and one antisense primer in the exon (5'-ATGAAAGTAAAAGAGGAGAAACTC-3').
Biochemical and biological assays of the MET Y1235D receptor
The Y1235D mutation was introduced in the human MET cDNA using a PCR-based technique as described (Bardelli et al., 1998) . Expression in cultured cells and phosphorylation assays were carried out as described (Longati et al., 1994; Bardelli et al., 1998) . Immunoprecipitation with anti-MET antibodies was performed from lysates of COS7 cells expressing either MET wt or MET
Y1235D
. Wild-type and mutation-carrying TRK-MET chimerical receptors were constructed as described . Invasion assay was performed as described . Generation of stably transfected MPL29 cells was as described (Medico et al., 1996) .
